Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1987 1
1991 1
1992 1
1995 1
1997 1
1999 1
2000 2
2001 1
2002 4
2003 4
2004 3
2006 3
2007 4
2008 5
2009 3
2010 4
2011 5
2012 5
2013 6
2014 12
2015 10
2016 12
2017 8
2018 6
2019 18
2020 21
2021 12
2022 15
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Genomic-Glycosylation
Page 1
Genetics of MDS.
Ogawa S. Ogawa S. Blood. 2019 Mar 7;133(10):1049-1059. doi: 10.1182/blood-2018-10-844621. Epub 2019 Jan 22. Blood. 2019. PMID: 30670442 Free PMC article. Review.
Significant correlations between mutations suggest the presence of functional interactions between mutations, which dictate disease progression. Mutations are frequently associated with specific disease phenotype, drug response, and clinical outcomes, and thu …
Significant correlations between mutations suggest the presence of functional interactions between mutations, which dictate disease …
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E. Nadeu F, et al. Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2. Blood. 2016. PMID: 26837699 Free PMC article.
Genomic studies have revealed the complex clonal heterogeneity of chronic lymphocytic leukemia (CLL). The acquisition and selection of genomic aberrations may be critical to understanding the progression of this disease. ...These findings suggest that the cha …
Genomic studies have revealed the complex clonal heterogeneity of chronic lymphocytic leukemia (CLL). The acquisition and selection of genom …
Oncometabolites in renal cancer.
Yong C, Stewart GD, Frezza C. Yong C, et al. Nat Rev Nephrol. 2020 Mar;16(3):156-172. doi: 10.1038/s41581-019-0210-z. Epub 2019 Oct 21. Nat Rev Nephrol. 2020. PMID: 31636445 Free PMC article. Review.
Their discovery has led researchers to revisit the Warburg hypothesis, first postulated in the 1950s, of aberrant metabolism as an aetiological determinant of cancer. As such, the identification of oncometabolites and their utilization in diagnostics and prognostics, as no …
Their discovery has led researchers to revisit the Warburg hypothesis, first postulated in the 1950s, of aberrant metabolism as an ae …
Pathogenesis and treatment of multiple myeloma.
Yang P, Qu Y, Wang M, Chu B, Chen W, Zheng Y, Niu T, Qian Z. Yang P, et al. MedComm (2020). 2022 Jun 2;3(2):e146. doi: 10.1002/mco2.146. eCollection 2022 Jun. MedComm (2020). 2022. PMID: 35665368 Free PMC article. Review.
Multiple myeloma (MM) is the second-ranking malignancy in hematological tumors. The pathogenesis of MM is complex with high heterogeneity, and the development of the disease is a multistep process. Chromosomal translocations, aneuploidy, genetic mutations, and epige …
Multiple myeloma (MM) is the second-ranking malignancy in hematological tumors. The pathogenesis of MM is complex with high heterogen …
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
Kapoor P, Ansell SM, Braggio E. Kapoor P, et al. Cancer Treat Res. 2016;169:321-361. doi: 10.1007/978-3-319-40320-5_16. Cancer Treat Res. 2016. PMID: 27696269 Review.
Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate th …
Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamen …
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Friedlaender A, Banna G, Patel S, Addeo A. Friedlaender A, et al. Curr Treat Options Oncol. 2019 Sep 4;20(10):79. doi: 10.1007/s11864-019-0675-9. Curr Treat Options Oncol. 2019. PMID: 31482479 Review.
There has been rapid progress in the use of targeted therapies for ALK-positive which has led to improve dramatically PFS and OS in the metastatic ALK-rearranged NSCLC patients. ...Several more expensive and time-consuming methods are also available nowadays which have the …
There has been rapid progress in the use of targeted therapies for ALK-positive which has led to improve dramatically PFS and OS in t …
Advances in molecular evaluation of myeloproliferative neoplasms.
Li N, Chen M, Yin CC. Li N, et al. Semin Diagn Pathol. 2023 May;40(3):187-194. doi: 10.1053/j.semdp.2023.04.007. Epub 2023 Apr 13. Semin Diagn Pathol. 2023. PMID: 37087305 Review.
Genome-wide sequencing analyses have discovered secondary cooperating mutations that are shared by most of the MPN subtypes as well as other myeloid neoplasms and play a major role in disease progression. Without appropriate management, the natural his …
Genome-wide sequencing analyses have discovered secondary cooperating mutations that are shared by most of the MPN subtypes as well as other …
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C, Wu C, Guo W, Xie Y, Li S, Liu W, Xu C, Li H, Cao P, Yang Y, Wang X, Chang A, Feng Y, Hao J. She C, et al. J Exp Clin Cancer Res. 2023 Sep 11;42(1):238. doi: 10.1186/s13046-023-02814-x. J Exp Clin Cancer Res. 2023. PMID: 37697370 Free PMC article.
RUNX1, a key transcription factor in hematopoiesis, also involved in the malignant progression of PDAC, but was unclear in the chemoresistance of PDAC. ...Silencing of RUNX1 could attenuate resistance in GEM-resistant cell line, and its inhibitor Ro5-3335 displayed an enha …
RUNX1, a key transcription factor in hematopoiesis, also involved in the malignant progression of PDAC, but was unclear in the chemor …
Role of RNF20 in cancer development and progression - a comprehensive review.
Sethi G, Shanmugam MK, Arfuso F, Kumar AP. Sethi G, et al. Biosci Rep. 2018 Jul 12;38(4):BSR20171287. doi: 10.1042/BSR20171287. Print 2018 Aug 31. Biosci Rep. 2018. PMID: 29934362 Free PMC article. Review.
Evolving strategies to counter cancer initiation and progression rely on the identification of novel therapeutic targets that exploit the aberrant genetic changes driving oncogenesis. ...An exciting really interesting new gene (RING) family of E3 ubiquitin li …
Evolving strategies to counter cancer initiation and progression rely on the identification of novel therapeutic targets that …
Therapeutic Use of MicroRNAs in Cancer.
Tessitore A, Cicciarelli G, Mastroiaco V, Vecchio FD, Capece D, Verzella D, Fischietti M, Vecchiotti D, Zazzeroni F, Alesse E. Tessitore A, et al. Anticancer Agents Med Chem. 2016;16(1):7-19. doi: 10.2174/1871520615666150824153358. Anticancer Agents Med Chem. 2016. PMID: 26299662 Review.
MicroRNAs are small non-coding RNAs which regulate gene expression and silence a wide set of target genes. Aberrant miRNA expression has been described in cancer cells and is at least in part responsible of cancer initiation, development and progression. ...R …
MicroRNAs are small non-coding RNAs which regulate gene expression and silence a wide set of target genes. Aberrant miRNA expression …
168 results